drugset / Trial / NCT01123356
Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab
Phase 2
Completed
21 enrolled
Medical University of South Carolina
Celgene Corporation · collabGlaxoSmithKline · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research is to evaluate the safety and effectiveness of the drugs lenalidomide and ofatumumab in the treatment of chronic lymphocytic leukemia (CLL).
Timeline
- Start
- 2010-05
- Primary completion
- 2013-05
- Completion
- 2013-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 10 mg | Oral |
| Subject | Ofatumumab | Monoclonal antibody | 2000 mg | Intravenous |